Mendus AB (publ) IMMU
Updated: 10 Aug 2026
No signal published yet
We already track Mendus and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Mendus AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Mendus free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In July 2026, Mendus announced the completion of patient enrollment for the first stage of its VITAL-CML trial evaluating vididencel. The company also entered into a collaboration with the South Australian Health and Medical Research Institute to prepare for the Phase 2a VITAL-TFR2 trial in chronic myeloid leukemia. Additionally, Mendus updated its share capital following a directed issue and conversion of Class C shares.
What Firelda Watch includes for Mendus AB (publ)
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Mendus AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Mendus free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more